Concarlo Holdings
CEO: Dr. Stacy Blain
Concarlo Holdings, LLC (Concarlo) is an oncology company focused on diagnosing and treating cancer by targeting a unique cellular pathway.
Their approach is based on the role of p27Kip1 — a key “ON-OFF” switch that modulates the activities of critical proteins involved in many cancers: CDK4, CDK6, and CDK2. Concarlo is initially focused in commercializing therapeutics to treat metastatic breast cancer alongside a diagnostic to identify patients who will respond to therapy.